
Support table**Table 1. Relationship between PLD1 expression and clinicopathologic factors of patients with Gastric carcinoma.**

Parameter	No. of patients	PLD1(low)	PLD1 (high)	P -value
Sex				0.5604
male	64	29	35	
female	56	22	34	
Age (yr)				0.2041
< 60	69	32	37	
≥ 60	51	20	31	
Tumor differentiation				0.0054
I	6	4	2	
II	65	22	43	
III	49	18	31	
Tumor size (cm)				0.0211
≤5	42	19	23	
>5	78	26	52	
Differentiation grade				0.0891
Well-moderate	58	23	35	
Poor-undifferentiation	62	30	32	
T stage				0.0042
T1-T3	41	19	22	
T4	79	15	64	
Lymph node status				0.412
Negative	57	30	27	
Positive	63	28	35	
Distant metastasis				0.2137
M0	59	34	25	
M1	61	24	37	
TNM stage				0.0654
I-II	56	26	30	
III-IV	64	21	43	
Lymphatic invasion				0.0621
Negative	51	26	25	
Positive	69	24	45	
Venous invasion				0.0511
Negative	68	31	37	
Positive	52	27	25	

Table 2. Univariate analysis identifies factors influencing the overall survival rate of Gastric carcinoma patients.

Factors	HR	95% CI	P value
Sex	0.997	1.01-2.35	0.481
Age (>60 vs. ≤60)	1.365	0.902-2.624	0.523
Tumor size(cm)>5	5.627	5.014-17.65	0.0234
Tumor size(cm)<5	3.124	0.734-4.012	0.0602
Differentiation grade	2.221	1.356-3.621	0.0341
T stage	1.89	1.237-2.702	0.0045
Lymph node status	2.967	0.98-3.02	0.013
Distant metastasis	2.24	0.896-2.354	0.367
TNM stage (III vs. II vs. I)	1.4.5	1.001-3.254	0.0211
Lymphatic invasion	1.67	1.07-3.024	0.0071
Venous invasion	1.79	1.09-3.32	0.436
PLD1 expression	2.57	1.96-2.986	0.0024

HR: hazard ratio; CI: confidence interval; TNM: tumor–node–metastasis classifications.

Table 3. Multivariate analysis identifies factors influencing the overall survival rate of Gastric carcinoma patients.

Factors	HR	95% CI	P value
Tumor size(cm)>5 vs. ≤5	1.97	1.21-2.64	0.027
Differentiation	1.79	1.01-2.45	0.320
T stage	0.97	0.78-2.14	0.001
Lymph node status	2.63	1.14-2.34	0.053
TNM stage(III vs. II vs. I)	1.25	1.13-1.97	0.011
Lymphatic invasion	0.97	1.02-3.13	0.081
Venous invasion	1.103	2.01-3.436	0.425
PLD1 expression	2.33	1.15-3.26	0.002

HR: hazard ratio; CI: confidence interval; TNM: tumor–node–metastasis classifications.